<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671864</url>
  </required_header>
  <id_info>
    <org_study_id>P150601</org_study_id>
    <nct_id>NCT02671864</nct_id>
  </id_info>
  <brief_title>Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy</brief_title>
  <acronym>ANGIOSAFE2</acronym>
  <official_title>Impact of Incretin-mimetic Hypoglycaemic Drugs on Diabetic Retinopathy in Type 2 Diabetic Patients and Study of Biomarkers in the Development of Severe Retinopathy: Angiosafe-T2D Study 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Collège de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Paris 7 - Denis Diderot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aix Marseille Université</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental data suggest that GLP-1 promote endothelial cell growth and angiogenesis which&#xD;
      may have beneficial effects on the cardiovascular system but harmful effects on the retina .&#xD;
      This project investigate the possible link between incretin therapy and Severe Diabetic&#xD;
      Retinopathy. The prevalence of severe DR in patients exposed to incretin therapy (GLP-1&#xD;
      analogs or DPP4 inhibitors) is compared to that in non-exposed patients to these antidiabetic&#xD;
      classes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is dedicated to investigate the impact of routinely prescribed hypoglycaemic&#xD;
      treatments on the prevalence of severe retinopathy and to seek possible biomarkers of severe&#xD;
      retinopathy. Hypoglycemic treatments taken by the patients are those prescribe by the usuel&#xD;
      diabetogist in the context of routine care.&#xD;
&#xD;
      The study includes T2D patients according to ADA criteria treated with any kind of&#xD;
      hypoglycemic treatment and attending a diabetes center (three in Marseille: Department of&#xD;
      Endocrinology, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille and Service&#xD;
      d'Ophtalmologie, Hôpital Saint-Joseph and Service de Diabétologie, Hôpital Saint-Joseph, and&#xD;
      two in Paris : Centre Universitaire du Diabète et de ses Complications Hôpital Lariboisière,&#xD;
      Université Paris 7, Assistance Publique des Hôpitaux de Paris and Service d'Endocrinologie,&#xD;
      Diabétologie et Nutrition, Hôpital Bichat).&#xD;
&#xD;
      It consists of two visits: Visits1 &quot;Inclusion&quot; and Visits 2 &quot;three years after the&#xD;
      inclusion&quot;. In each visit, the investigators will collect results of eye examination (fundus)&#xD;
      and annual diabetes check up including anthropometric data, routine biology, diabetes&#xD;
      complication status as well as medications taken by the patients (past and current). A&#xD;
      bio-banking (blood, urine and hairs) will be also collected. Primary objective : to compare&#xD;
      the prevalence of severe DR in patients exposed to incretin therapy (GLP-1 analogs or DPP4&#xD;
      inhibitors) to that in non-exposed patients at baseline.&#xD;
&#xD;
      Secondary objective: To compare the proportion of patients who worsen DR between V1&#xD;
      (inclusion) and V2 (after 3-yr of treatment) in patients exposed to incretin-based therapy&#xD;
      from baseline vs non-exposed patients: patients with no DR or mild to moderate non&#xD;
      proliferative DR at V1 who progress to severe DR at V2.&#xD;
&#xD;
      To evaluate whether the concentrations of angiogenic/inflammatory molecules and circulating&#xD;
      endothelial and inflammatory cells are associated with severe DR in relation with the use of&#xD;
      GLP-1 based therapy at V1 and V2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2016</start_date>
  <completion_date type="Anticipated">April 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Severe DR at V1 (inclusion)</measure>
    <time_frame>at inclusion</time_frame>
    <description>Retinography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of severe DR at V2 (after 3 years of treatment)</measure>
    <time_frame>after 3 years</time_frame>
    <description>Retinography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of ANGPT4</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of VEGF</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of proinflammatory cytokines such as IL-1beta, IL-6, IL-8, TNF-alpha</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of blood circulating EPCs and PBMCs</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1: incretin-based therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with incretin-based therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: other antidiabetic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with other antidiabetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1: incretin-based therapy</intervention_name>
    <arm_group_label>1: incretin-based therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2: other antidiabetic</intervention_name>
    <arm_group_label>2: other antidiabetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T2D patients according to ADA criteria treated with any kind of hypoglycaemic&#xD;
             treatment&#xD;
&#xD;
          -  Age above 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Patients with cataract preventing DR grading&#xD;
&#xD;
          -  Patients who had panretinal photocoagulation more than 10 years ago&#xD;
&#xD;
          -  Documented pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GAUTIER Jean-François, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GAUTIER Jean-François, MD, PhD</last_name>
    <phone>33 1 49 95 90 20</phone>
    <email>jean-francois.gautier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DUTOUR Anne, MD, PhD</last_name>
    <phone>33 4 91 38 29 63</phone>
    <email>anne.dutour@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DUTOUR, MD, PhD</last_name>
      <phone>33 4 91 38 29 63</phone>
      <email>anne.dutour@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bénédicte GABORIT, MD, PhD</last_name>
      <phone>33 491383650</phone>
      <email>benedicte.gaborit@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Département de Diabétologie - Hopital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GAUTIER Jean-François, MD, PhD</last_name>
      <phone>33 1 49 95 90 20</phone>
      <email>jean-francois.gautier@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Incretin-based therapy</keyword>
  <keyword>GLP1</keyword>
  <keyword>Angiogenesis Inflammation</keyword>
  <keyword>Hypoglycaemic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

